Hydrofluoroalkane-134a beclomethasone as a dominant economic asthma therapy

D. C. Malone, A. T. Luskin

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Inhaled corticosteroids for asthma treatment have become mainstay of therapy for patients with persistent asthma. Numerous inhaled corticosteroids are available but to date no prospective cost-effectiveness studies have been reported using exclusively US patients and costs. The purpose of this study was to examine the cost-effectiveness of HFA-beclomethasone (QVAR™) compared to CFC-beclomethasone (Vanceril™) using data from a year-long prospective randomized, open label, parallel multicenter trial. Eligibility criteria required patients to have been on a stable dose of CFC-BDP prior to enrollment. Patients were randomized to either HFA-BDP at approximately half their previous daily dose of CFC-BDP or to continue CFC-BDP. Effectiveness data, in terms of symptom-free days (SFDs), were used in a cost-effectiveness analysis conducted from the viewpoint of managed care. Patients receiving HFA-BDP reported a greater increase (median = 22.1) in the number of SFDs than those receiving CFC-BDP (median = 14.3) (P = 0.03). Total costs of care were less for patients taking HFA-BDP (median = $668) compared to CFC-BDP (median = $977). The median incremental cost-effectiveness ratio was -$5.77 (95% CI:-$68.08 to -$4.08). The results of this analysis indicate that HFA-BDP was a dominant therapy (more effective, less costly) compared to CFC-BDP.

Original languageEnglish (US)
Pages (from-to)1269-1276
Number of pages8
JournalRespiratory Medicine
Issue number12
StatePublished - Dec 2003
Externally publishedYes


  • Asthma
  • Beclomethasone
  • CFC-free
  • Cost-effectiveness
  • Economics
  • Hydrofluoroalkane

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Hydrofluoroalkane-134a beclomethasone as a dominant economic asthma therapy'. Together they form a unique fingerprint.

Cite this